Allergan chief looks for new treatments

The head of Botox-maker Allergan has said that the company may be interested in buying up drugs designed to treat urology ailments and neurological conditions.

Chief executive David Pyott told Reuters in an interview that urologists and neurologists would also grow to be important to the firm, as Botox could be allowed for use by migraine sufferers.

“We would be interested in anything used by neurologists, such as treatments for epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and pain medication,” he said.

“And in urology, it could be drugs or devices for bladder and prostate problems.”

Allergen is in the process of purchasing breast implant maker Inamed Corporation. On Monday the firm extended the deadline of its offer for the company to February 22nd, as it has yet to receive US antitrust approval for the move.

During the third quarter of 2005 Allergen generated $227.3 million in Botox sales, bringing its net earnings for the period to $122 million. As well as its use as an anti-wrinkle treatment, Botox has been approved for use in excessive sweating and for reducing eye blinking.

© Adfero Ltd